Biotechnology Ultrasector Correlations

BIPIX Fund  USD 68.95  1.26  1.86%   
The current 90-days correlation between Biotechnology Ultrasector and Nasdaq 100 2x Strategy is 0.61 (i.e., Poor diversification). The correlation of Biotechnology Ultrasector is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.

Biotechnology Ultrasector Correlation With Market

Poor diversification

The correlation between Biotechnology Ultrasector Prof and DJI is 0.64 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Biotechnology Ultrasector Prof and DJI in the same portfolio, assuming nothing else is changed.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biotechnology Ultrasector Profund. Also, note that the market value of any mutual fund could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

Moving against Biotechnology Mutual Fund

  0.35ENPSX Oil Gas Ultrasector Potential GrowthPairCorr
  0.38RRPSX Rising Rates OpportunityPairCorr
  0.37BTCFX Bitcoin Strategy ProfundPairCorr
  0.35ENPIX Oil Gas Ultrasector Potential GrowthPairCorr
  0.41RDPIX Rising Dollar ProfundPairCorr
  0.41RDPSX Rising Dollar ProfundPairCorr
  0.37RRPIX Rising Rates OpportunityPairCorr
  0.32RTPSX Rising Rates OpportunityPairCorr

Related Correlations Analysis

Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Risk-Adjusted Indicators

There is a big difference between Biotechnology Mutual Fund performing well and Biotechnology Ultrasector Mutual Fund doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Biotechnology Ultrasector's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.